A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)

[1]  C. Langer,et al.  A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99 , 2008 .

[2]  Boris Freidlin,et al.  Proposal for the use of progression-free survival in unblinded randomized trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Yiannoutsos,et al.  A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Angeletti,et al.  Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  K. Mori,et al.  Multidisciplinary Treatment for Advanced Invasive Thymoma with Cisplatin, Doxorubicin, and Methylprednisolone , 2005, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  G. Giaccone.  Treatment of malignant thymoma , 2005, Current opinion in oncology.

[7]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[8]  Charles R. Thomas,et al.  Thymic carcinoma: state of the art review. , 2004, International journal of radiation oncology, biology, physics.

[9]  Edward S. Kim,et al.  Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. , 2004, Lung cancer.

[10]  H. Müller-Hermelink,et al.  Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Onishi,et al.  Postoperative radiotherapy for patients with completely resected thymoma , 2002, Cancer.

[12]  H. Matsuda,et al.  The World Health Organization histologic classification system reflects the oncologic behavior of thymoma , 2002, Cancer.

[13]  K. Cornetta,et al.  High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience , 2001, Bone Marrow Transplantation.

[14]  Charles R. Thomas,et al.  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma , 2001, Cancer.

[15]  M. Brizzi,et al.  Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience , 1999, British Journal of Cancer.

[16]  P. Loehrer,et al.  Thymoma: state of the art. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Saijo,et al.  Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Chen,et al.  Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Giaccone,et al.  Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Livingston,et al.  Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Shimada,et al.  Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. , 1993, Japanese journal of clinical oncology.

[22]  D. Osoba,et al.  Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Urgesi,et al.  Role of radiation therapy in locally advanced thymoma. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  A. Paccagnella,et al.  Chemotherapy of invasive thymoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Curran,et al.  Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Murray.  The importance of dose and dose intensity in lung cancer chemotherapy. , 1987, Seminars in oncology.

[27]  W. Hryniuk,et al.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J H Goldie,et al.  The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.

[29]  Goldie Jh,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983 .

[30]  Y. Monden,et al.  Follow‐up study of thymomas with special reference to their clinical stages , 1981, Cancer.

[31]  N. Girard,et al.  Thymoma: a focus on current therapeutic management. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  M. Fukuoka,et al.  CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. , 1997, British Journal of Cancer.

[33]  J. Goldie,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983, Cancer treatment reports.

[34]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.